(CercleFinance.com) – Novavax announced today that Medsafe, the New Zealand health authority, has granted extended provisional approval for the firm’s Covid vaccine, Nuvaxovid, for 12-17 year olds.
‘We are delighted to offer a choice of protein-based vaccines against COVID-19 as a primary series for New Zealanders aged 12 and over and as a booster for adults aged 18 and over’, said Stanley C. Erck, CEO. from Novavax.
The tentative approval is based on data from a phase 3 trial showing the vaccine’s overall clinical efficacy of 80% in 12-17 year olds, at a time when the Delta variant was the SARS-CoV strain -2 predominant in circulation in the United States.
Novavax says that in the 12-17 year old population, its vaccine has already obtained approval in India, the European Union, Australia, Japan and Thailand, and is actively under review on d other markets.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
